Beam Therapeutics Inc.
Price Action
Technical Summary
EMERGING TRENDBeam Therapeutics Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 314% provides fundamental context to the price action. Investors should exercise caution due to high volatility (74% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $29.95 | +7.97% | ABOVE |
| 50 SMA | $27.30 | +18.43% | ABOVE |
| 100 SMA | $27.97 | +15.62% | ABOVE |
| 150 SMA | $26.98 | +19.83% | ABOVE |
| 200 SMA | $25.18 | +28.41% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BEAM in an uptrend right now?
BEAM has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is BEAM overbought or oversold?
BEAM's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is BEAM outperforming the market?
BEAM has a Relative Strength (RS) Rating of 80 out of 99. Yes, BEAM is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is BEAM in its 52-week range?
BEAM is trading at $32.33, which is 89% of its 52-week high ($36.44) and 81% above its 52-week low ($15.35).
How volatile is BEAM?
BEAM has a Beta of 2.14 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.